​New Clinical Results from RheOx^TM System for Chronic Bronchitis to be Presented at European Respiratory Society (ERS) International Congress

Menlo Park, Calif. – Sept. 26, 2019 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced that clinical results and a patient case involving its RheOx^TM Bronchial Rheoplasty system will be presented at the 2019 ERS International Congress,

…

Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOx^TM System for Chronic Bronchitis

Menlo Park, CA Sept. 16, 2019 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (FDA) for the RheOx^TM Bronchial Rheoplasty^TM system.

…

Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx^TM System for Chronic Bronchitis

First-of-its-kind RheOx device designed to reduce mucus-producing cells and improve quality of life 

Menlo Park, CA Sept. 4, 2019 – Gala Therapeutics, Inc. (Gala) today announced that its RheOx^TM system has received CE Mark in the European Union.

…

Initial Study of the Minimally Invasive RheOx^TM Device Demonstrates Positive Results for Chronic Bronchitis Patients

Dallas, Texas, May 22, 2019 – Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced new results from the initial study of its investigational RheOx^TM device,

…

New Data from First-in-Human Study of RheOx^TM Device-Based Therapy for Chronic Bronchitis to be Presented at ATS 2019

Menlo Park, Calif., May 16, 2019 – Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from the first-in-human study of its investigational RheOx^TM device will be presented at the 2019 American Thoracic Society (ATS) International Conference,

…

Gala Enrolls First Subject at Temple Lung Center as Part of the US Early Feasibility Trial of RheOx^TM for Chronic Bronchitis in the United States

Menlo Park, Calif, November 5, 2018 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that the first patient at Temple Lung Center in Philadelphia,

…

Pittsburgh’s KDKA Publishes Story on the First Patient Treated with RheOx^TM in the United States

…

Gala Enrolls First Subjects in an Early Feasibility Study of RheOx^TM for Chronic Bronchitis in the United States

Menlo Park, Calif, November 5, 2018 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that the first two patients in the Early Feasibility Study of RheOx^TM for Chronic Bronchitis were treated at University of Pittsburgh Medical Center (UPMC) in Pittsburgh,

…

Gala Presents Positive Results from First-In-Human Clinical Trial of RheOx^TM in Chronic Bronchitis at the European Respiratory Society

• Favorable safety profile
• RheOx treatment resulted in clinical improvement as measured by Quality of Life scores, with treatment effect maintained at 12-month follow-up
• Improvement in airway biopsies and imaging

Menlo Park,

…

Data From First-In-Human RheOx^TM Bronchial Rheoplasty Trial to be Presented at the European Respiratory Society

Menlo Park, Calif, August 8, 2018 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from a Late-Breaking Abstract from a first-in-human study of the Rheox^TM system will be presented at the European Respiratory Society (ERS) in Paris,

…